Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;32(10):e211.
doi: 10.1016/j.clon.2020.06.006. Epub 2020 Jul 11.

Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience

A Patibandla  1 , C Featherstone  1 , V Maclaren  1 , G Lumsden  1 , S Harrow  1 , R Jones  1 , A J Chalmers  2 , P McLoone  3 , J Hicks  1
Affiliations
Comment

Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience

A Patibandla et al. Clin Oncol (R Coll Radiol). 2020 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Faivre-Finn C., Fenwick J.D., Franks K.N., Harrow S., Hatton M.Q.F., Hiley C. Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic. Clin Oncol. 2020 doi: 10.1016/j.clon.2020.05.001. - DOI - PMC - PubMed
    1. Maguire J., Khan I., McMenemin R., O’Rourke N., McNee S., Kelly V. SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer. 2014;50:2939–2949. - PubMed
    1. Bradley J., Paulus R., Komaki R., Masters G., Blumenschein G., Schild S. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–199. - PMC - PubMed
    1. Senan S., Brade A., Wang L., Vansteenkiste J., Dakhil S., Biesma B. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2016;34(9):953–962. - PubMed
    1. Gray J.E., Villegas A., Daniel D., Vincente D., Murakami S., Hui R. Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-Update From PACIFIC. J Thorac Oncol. 2020;15(2):288–293. doi: 10.1016/j.jtho.2019.10.002. - DOI - PMC - PubMed